Extensive Circumferential Partial Thickness Sclerectomy in Nanophthalmic Eyes

Sponsor
Rafic Hariri University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03748732
Collaborator
(none)
30
1
108
0.3

Study Details

Study Description

Brief Summary

Purpose: To describe an extensive scleral excision technique to treat or prevent uveal effusion in nanophthalmic eyes.

Design: Prospective interventional case series.

Methods:
  • Setting: Institutional.

  • Patient Population: Consecutive patients with nanophthalmos were operated on by one surgeon.

  • Intervention Procedure: A single, 90% thickness scleral window extending from immediately behind the extraocular muscle insertions to the vortex veins was performed for 3 and 1/4 quadrants as a circumferential strip.

  • Main Outcome Measure: Resolution or prevention of uveal effusion.

Condition or Disease Intervention/Treatment Phase
  • Procedure: sclerectomy
N/A

Detailed Description

Surgical Technique All surgeries were performed under general anesthesia by one surgeon (AMM). Because the majority of the patients were young with narrow palpebral fissures and very deep set globes in small orbits, special surgical techniques were required. Lateral canthotomy was performed on all patients except for the first. Limbal 360o conjunctival peritomy was followed by securing of each rectus muscles with a modified muscle hook and 2-0 silk suture. Scleral dissection was performed from immediately behind to the muscle insertions posterior to the vortex veins. A 90% depth scleral window was excised over 3 and ΒΌ quadrants, excluding 3/4 of the superior temporal quadrant to avoid damaging the superior oblique muscle.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
surgerysurgery
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Extensive Circumferential Partial Thickness Sclerectomy in Nanophthalmic Eyes
Actual Study Start Date :
Jan 1, 2011
Anticipated Primary Completion Date :
Jan 1, 2020
Anticipated Study Completion Date :
Jan 1, 2020

Outcome Measures

Primary Outcome Measures

  1. resolution of uveal effusion [1 month]

    disappearence of uveal effusion by OCT

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria: nanophthalmos -

Exclusion Criteria: None

-

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rafic Hariri University Hospital Beirut South Beirut Lebanon 1136044

Sponsors and Collaborators

  • Rafic Hariri University Hospital

Investigators

  • Study Chair: Ahmad Mansour, MD, Rafic Hariri University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ahmad Mansour, MD, Clinical Professor, AUB, Professor, Rafic Hariri University Hospital
ClinicalTrials.gov Identifier:
NCT03748732
Other Study ID Numbers:
  • RaficHaririUHAMM
First Posted:
Nov 21, 2018
Last Update Posted:
Nov 21, 2018
Last Verified:
Nov 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ahmad Mansour, MD, Clinical Professor, AUB, Professor, Rafic Hariri University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 21, 2018